Pathogen detection remains one of the strangest bottlenecks in modern industry. A hospital can sequence a genome, a dairy operation can track every animal by sensor, a food plant can automate an entire line, and yet the question of what organism is present still travels by courier to a central laboratory and comes back hours or days later. By then the patient has been treated empirically, the flock has been exposed, or the contaminated batch has shipped. Dr. Leonard E. Weisman, Founder and Chief Technology Officer of LabReady, argues that the failure is not scientific but architectural. The chemistry works. The deployment model does not. A virus, as he puts it, does not care whether it lands in a hospital, a chicken house, or a food processing plant. It spreads, it costs lives, and it costs billions. The detection infrastructure built around that reality has mostly been designed for the convenience of laboratories rather than for the places where decisions are made.
Design For The Environment, Not The Laboratory
The first mistake, in Weisman’s reading, is one of imagination. Diagnostic developers picture a clean bench, a trained technician, controlled temperature, and unlimited time. The real deployment sites look nothing like that. “A clinic, a dairy farm, and a food plant do not look like a research bench,” he says. “They are fast, messy, resource-constrained.” That gap is where most promising assays quietly die. A test that performs beautifully in validation and requires a specialist to run it has not solved the problem; it has relocated the problem to somewhere the customer cannot reach.
His standard is blunt. “If your diagnostic requires a technician, a cold chain, and a courier, it has already failed.” Read that as a procurement filter rather than a slogan. Every dependency a device carries is a point where the field environment can break it, and the cumulative cost of those dependencies, in staff, logistics, and refrigeration, usually exceeds the cost of the test itself. The design requirements that follow are unglamorous: simple workflows, rugged hardware, and results in minutes rather than days. None of that advances the underlying science. All of it determines whether the science ever gets used. The industry has spent years optimizing sensitivity while treating usability as a packaging decision, which is precisely backwards when the alternative to a field-ready test is no test at all.
Build A Platform, Not A Product
The second principle attacks a more expensive habit. Diagnostics are typically funded, developed, and regulated around a single target, which means each new pathogen restarts the cycle: new device, new validation, new capital, new sales effort. Weisman wants the opposite architecture. “A great diagnostic platform should detect what matters today and adapt to what matters tomorrow,” he says, naming three cases that look unrelated on an org chart but are nearly identical at the molecular level. “Whether it’s a respiratory virus in a child, avian flu in a flock, or contamination on a production line, the underlying chemistry and AI should stay the same.”
The commercial logic here deserves more attention than the technical claim. “Reusability is what turns a product into an industry standard,” he says, and that sentence contains the whole strategy. Single-target devices compete on price in narrow markets and get displaced when the target changes. A platform that holds its chemistry constant across human health, animal health, and food safety spreads development cost across three buyer categories and converts every new pathogen into a software and assay update rather than a new hardware program. It also changes the risk profile for anyone funding the work. Investors backing a problem-specific test are betting on one pathogen staying relevant. Investors backing a platform are betting on the general proposition that pathogens keep appearing, which is the safer bet by a wide margin.
Put The Intelligence At The Edge
The third principle names the real constraint. “Sending samples to a laboratory is the bottleneck,” Weisman says, and the point is worth sitting with, because the laboratory is usually treated as the solution rather than the delay. Centralized testing concentrates expertise in one place and then makes everyone wait for it. The alternative is not a faster courier. It is moving the interpretive capability into the device itself, where the sample already is. “When you combine PCR [polymerase chain reaction] with onboard AI, the device itself becomes the expert,” he says. “It interprets, it decides, and it delivers an answer where the patient, animal, or product is.”
What that unlocks is an economics problem rather than an accuracy problem. “That is how you scale accuracy without scaling cost,” Weisman says. Expert interpretation has always been the expensive, non-scalable input in diagnostics, the reason testing capacity cannot simply be bought during a surge. Embedding that judgment in hardware breaks the link between the number of tests run and the number of trained interpreters required, which is the only path to coverage at agricultural or industrial scale. His conclusion reframes where the next decade of investment should go. “The future of detection is not a bigger lab, it’s a smarter device, in more hands, in more places.” For anyone still building capacity by adding square footage to central facilities, that is a direct challenge to the plan.
Follow Dr. Leonard E. Weisman on LinkedIn for more insights on point-of-need diagnostics, PCR platform design, and edge AI in pathogen detection.
